In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jennerex Biotherapeutics Inc.

Division of SillaJen Inc.
www.jennerex.com

Latest From Jennerex Biotherapeutics Inc.

Appointments: GSK, Neurocrine Biosciences, Cue Biopharma, BenevolentAI And Ferring Pharmaceuticals

This week's roundup includes two executive appointments by GSK, plus updates from Radius Health Inc., Cue Biopharma and BenevolentAI, with Myovant Sciences making four key management hires.

Appointments BioPharmaceutical

Deal Watch: Sandoz Licenses Posimir For Pain As Durect Generates Data For Resubmission

Sandoz acquires rights to extended-release bupivacaine once held by Nycomed and Hospira in deal paying Durect $20m up front. Video interview: Partners Elasmogen and Feldan collaborate with Amgen.

Deals M & A

SillaJen IPO Priced Low But Hopes High As Pexa-Vec Progresses

SillaJen, a South Korean venture that has been under investors' radars, is set to float at the lower end of its range as investors focus on the potential of its lead asset Pexa-Vec for liver cancer.

Commercial Companies

SillaJen’s Novel HCC Therapy Set For Phase III

SillaJen, a private South Korean clinical-stage biotherapeutics company focused on the development of immunotherapies for cancer, is set to begin a global Phase III clinical trial with its candidate Pexa-Vec later this year, following an agreement with the U.S. FDA on a Special Protocol Assessment (SPA).

BioPharmaceutical South Korea
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Jennerex Inc.
  • Jennerex Biotherapeutics ULC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • SillaJen Inc.
  • Senior Management
  • Laurent Fischer, MD, CEO
    Christopher Peetz, VP, Fin. & Corp. Dev.
    John Bell, PhD, CSO
    Lara Longpre, COO
  • Contact Info
  • Jennerex Biotherapeutics Inc.
    Phone: (415) 281-8886
    450 Sansome St.
    16th Floor
    San Francisco, CA 94111
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register